1,5-Anhydroglucitol in type 2 diabetes mellitus patients with ST elevation myocardial infarction.

Abstract

Aim: The study aimed to investigate the potential association of 1,5-AG and cardiovascular events in patients with type 2 diabetes mellitus. Methods: The study was an observational non-matched case-control study. The study included 114 patients with type 2 diabetes mellitus; 42 were with STEMI (STEMI group) and 72 without STEMI (non-STEMI group). Clinical data, fasting blood glucose, HbA1c, and 1,5 Anhydro-D-glucitol were analyzed. The Mann-Whitney U-test and the χ2 test was used for categorical variables to assess the significance of differences between the groups. The binary logistic regression was used to determine the association of 1,5-AG and STEMI. Results: There were 43.86% men and 56.14% women among the investigated patients. The median age of patients in the STEMI and non-STEMI groups were 61 (Q25-75 54-71) and 53 (Q25-15 75 57-60) years of age, р=0.027. Median fasting plasma glycemia in the STEMI group was 9.81 mmol/l (Q25-75 7.7-14.8), in the non-STEMI group (8.55 mmol/l, Q25-75 6.72-10.07, р=0.012). 1,5-AG was significantly lower in the STEMI group than in the non-STEMI (the STEMI group: Ме=215.85, Q25-75 186.35-19 280.77; the non-STEMI group Ме=314.64, Q25-75 250.83-415.08, р=0.000). No significant difference in concentration of HbA1c was found between the groups. The logistic regression model adjusted on confounders demonstrated that low plasma 1,5-AG concentration increases the odds ratio of STEMI in diabetic patients [OR 3,217 (95% CI 2,567–7,732), p = 0,002]. Conclusion: The association between 1,5-AG and STEMI in patients with T2DM suggests the potential beneficial role of 1,5-AG as a cardiovascular risk marker in patients with type 2 diabetes mellitus.